Introduction {#Sec1}
============

Transsphenoidal surgery (TS) is the treatment of choice for many pituitary tumors. TS may result in (additional) pituitary insufficiency in some of these patients \[[@CR1]--[@CR3]\]. Therefore, accurate assessment of pituitary function is essential for appropriate management of postoperative patients after TS. In this respect, evaluation of the pituitary-adrenal axis is clinically relevant to assess the need for hydrocortisone replacement therapy at discharge.

The insulin tolerance test (ITT) is considered to be the gold standard for the evaluation of secondary adrenal insufficiency \[[@CR4], [@CR5]\]. Because there are contraindications for ITT in some patients, the corticotrophin releasing hormone (CRH) test, the metyrapone test or the ACTH stimulation test can be used as alternative dynamic tests to assess adrenal function \[[@CR6]--[@CR8]\]. However, there is no international consensus for postoperative testing after pituitary surgery. We performed a structured literature search for articles that (1) evaluated the postoperative strategy for evaluation of adrenal function and (2) use of the CRH test to evaluate the pituitary-adrenal axis in postoperative patients after TS for pituitary adenomas, excluding manuscripts on patients with Cushing's disease. However, specific data on this topic are hardly available.

Moreover, studies that compared CRH test and other dynamic test in other situations (i.e. in patients with (suspected) hypothalamic-pituitary insufficiency not specifically related to surgery) reported contradictory results \[[@CR8], [@CR9]\]. Therefore, at our center we developed a strategy for evaluation of patients after pituitary surgery in 1990 using the CRH test as the first postoperative test. The aim of the present study was to assess the clinical relevance of the CRH stimulation test, as a part of this evaluation strategy, in assessing pituitary-adrenal function after TS. We performed a retrospective analysis of all patients treated by TS between January 1990 and November 2009, in whom a CRH test and a second stimulation test was performed to assess adrenal function during follow-up in non-Cushing patients.

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

We performed a retrospective chart review of all patients, who had been treated by TS in the Leiden University Medical Center between January 1990 (when human CRH (hCRH) became available for routine clinical use) and November 2009. Patients with available data on a postsurgical CRH-test, who also had a second (confirmation) test of adrenal function during follow-up were included. We excluded patients on high dose glucocorticoids, reoperation, postoperative cranial radiotherapy, and patients treated by TS for Cushing's disease.

The Medical Ethics Committee of our hospital declared that no formal ethical approval and written informed consent is needed for this anonymous retrospective chart review.

Endocrine assessment {#Sec4}
--------------------

According to the postoperative protocol, which has been implemented in our hospital, the pituitary-adrenal axis is assessed by CRH test 7--10 days after surgery. The CRH test is performed after an overnight fast, after withdrawal of hydrocortisone for 24 h, using 100 μg CRH (Corticoliberine, Ferring Farmaceuticals Hoofddorp, the Netherlands). Venous blood samples for measurement of ACTH and cortisol concentrations are collected at −15, 0, 15, 30, 45 and 60 min after infusion. A peak plasma cortisol of ≥550 nmol/L is considered to reflect a normal response \[[@CR10], [@CR11]\].

In case of insufficient cortisol responses to CRH, hydrocortisone is prescribed (20 mg/day, divided in three doses). During follow-up, the treating endocrinologist decided on re-testing of the adrenal function. For the assessment of the HPA axis during follow-up either basal serum cortisol levels or a stimulation test was used. The ITT was performed after an overnight fast by intravenous administration of insulin (0.10 U/kg, Actrapid, Novo Nordisk Farma, Bagsvaerd, Denmark) to induce adequate hypoglycemia, defined as nadir glucose levels \<2.2 mmol/L. Blood was collected for measurement of cortisol, ACTH and GH at −15, 0, 15, 30, 45, 60, 90 and 120 min after iv administration of insulin. Peak values of GH \>9 mU/L (corresponding with 3 μg/L) and cortisol of ≥550 nmol/L were considered to reflect normal pituitary function of GH and ACTH secretion \[[@CR4], [@CR12]--[@CR15]\].

For the ACTH test 1 μg Synacthen (Novartis Pharma, Arnhem, The Netherlands) was administered i.v. and cortisol levels were measured at −15, 0 and 30 min after infusion. A peak cortisol value of ≥550 nmol/L was considered to reflect normal adrenal reserve \[[@CR16]--[@CR18]\]. In addition, a basal serum cortisol concentration of \>550 nmol/L was considered to reflect normal adrenal function \[[@CR9]\].

In some patients a metyrapone test was used as a second test to assess pituitary adrenal function. Metyrapone (30 mg/kg, Metopiron, Novartis Pharma B.V., Arnhem, the Netherlands) was administered orally at midnight. The next morning postabsorptive blood samples were obtained for measurement of 11-deoxycortisol, cortisol and ACTH levels. A cut-off value for 11-deoxycortisol of 200 nmol/L was used to define normal adrenal function \[[@CR6], [@CR19], [@CR20]\].

Assays {#Sec5}
------

Between 1986 and 1994, a fluorescence energy-transfer immunoassay Syva-Advance (Syva Company, Palo Alto, CA) was used, with an interassay variation coefficient of 3.6--6.1% and a detection limit of 50 nmol/L. From 1994, cortisol was measured by fluorescencepolarization assay on a TDx (Abbott Laboratories, Abbott Park, IL). The interassay variation coefficient is 5--6% above 500 nmol/L and amounts to 12% under 200 nmol/L. The detection limit is 20 nmol/L. The methods correlated well with each other, and therefore no correction factors were introduced for follow-up of patients. ACTH was determined by immunolimunimetric assay using an Immulite 2500 (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The maximal inter-assay coefficient of variation (CV) was between 5.0 and 10.0%. During the insulin tolerance test glucose levels were measured using a Modular P800 (Roche Diagnostics, Mannheim, Germany).

For the measurement of 11-deoxycortisol a radioimmunoassay (RIA) of Diasource (previously Biosource Europe, Nivelles, Belgium) was used. CV was approximately 11%.

FT4, TSH, LH, FSH and prolactine blood levels were measured by electrochemoluminescent immunoassay (ECLIA), using a Modular E170, (Roche Diagnostics, Mannheim, Germany). The maximal inter-assay CV for these hormones was 5.0%. ACTH, GH and IGF-I were determined by immunolimunimetric assay using an Immulite 2500 (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The maximal inter-assay CV was between 5.0 and 10.0%. Glucose levels were measured using a Modular P800 (Roche Diagnostics Mannheim, Germany) (CV is 3%). For measurement of estradiol levels a RIA (Orion Diagnostica, Espoo, Finland) was used (CV is 6% at 70 pmol/L). The estradiol detection limit was 20 pmol/L. Testosterone was measured using a RIA (Siemens Healthcare Diagnostics, Deerfield IL, USA). (CV is 20% at 1.0 nmol/L and 12% at 14 nmol/L) The detection limit was 0.2 nmol/L.

Statistical analysis {#Sec6}
--------------------

PSAW for Windows version 17.0 (SPSS Inc. Chicago, IL) was used to perform data analysis. Data are presented as mean ± SD unless otherwise mentioned. To evaluate the difference between peak cortisol of the direct postsurgical CRH test and the confirmation test during follow-up we used a paired t-test. A χ^2^-test was used to evaluate the difference in prevalence of additional pituitary insufficiency in patients diagnosed with or without adrenal insufficiency based on the CRH stimulation test. The level of significance was set at *P* ≤ 0.05.

Results {#Sec7}
=======

Patients {#Sec8}
--------

Between January 1990 and November 2009, 291 patients were treated by TS for non-functioning pituitary adenomas (NFA, n = 160), GH-producing adenomas (n = 96), prolactinomas (n = 16) or other pituitary tumors (n = 19) (Fig. [1](#Fig1){ref-type="fig"}). A CRH test directly following surgery was not indicated in 13 patients because of cortisol levels below or above the reference rages of normal (\<100 nmol/L and \>550 nmol/L, respectively). In addition no CRH test was performed in 69 patients for several reasons: pituitary insufficiency prior to surgery n = 29, follow-up in outpatient clinic n = 11, peri-operative steroid use n = 5, ITT directly after surgery n = 7 and loss to follow-up n = 30. Consequently, a CRH test was performed in 209 postoperative patients after TS. In 65 of these 209 patients, there was no additional adrenal test performed in follow-up between TS and referral for postoperative radiotherapy (n = 24), repeat surgery (n = 5), or death of the patient (n = 10), or due to follow-up in another hospital (n = 17) and loss to follow-up (n = 9). Therefore, 144 patients were finally included in this study. Baseline characteristics of these 144 patients are presented in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow-chart of patient selection and follow-up.*AI* = adrenal insufficiency. \*pre-existent panhypopituitarism before or immediately after surgery (n = 12), pre-existent isolated severe adrenal insufficiency before surgery (n = 4) or very low basal serum cortisol concentrations (mean 10 nmol/L) during follow-up after surgery (n = 4). \*\*basal serum cortisol levels \> 550 nmol/L (n=12), normal urine cortisol levels (n=3), short follow-up between repeated surgery or additional radiotherapy (n = 2), and follow-up \<1 year (n = 2) or unspecified reasons (n = 7), basal serum cortisol \<110 nmol/L (n = 1)Table 1Baseline characteristicsBaseline characteristicsNumber of patients(n = 144)Gender (M/F)71/73Age (years)50 (15--83)Diagnosis (n) NFA70 Acromegaly63 Prolactinoma6 Other pituitary tumors5Time between CRH test and confirmation test (months)25.5 (2 days^a^-219 months)Confirmation test (n = 97) ITT55 CRH16 ACTH stimulation test21 Metyrapone test5^a^Basal serum cortisol was low, however CRH test peak cortisol 0.61 therefore 2 days after CRH test a metyrapone test was performed

Patients with a decreased postoperative cortisol response to CRH (n = 42) {#Sec9}
-------------------------------------------------------------------------

The peak levels of cortisol during the postoperative CRH-test classified 42 of the 144 patients with pituitary-adrenal insufficiency (peak cortisol \< 550 nmol/L) (Fig. [1](#Fig1){ref-type="fig"}). In 22 of these 42 patients with a median peak cortisol response to CRH of 480(30--547) nmol/L, a second stimulation test was performed during follow-up: ITT (n = 8), ACTH stimulation test (n = 8), CRH stimulation test (n = 5) and metyrapone test (n = 1). These confirmation tests were performed with a median interval of 27.5 (1--139) months after the initial postoperative CRH test. Based on this repeat test, 9 of these 22 (41%) patients had persistent adrenal insufficiency \[median initial cortisol response 356 (30--547); median cortisol response confirmation test 219 (3--514)\], who received hydrocortisone replacement and 13 (59%) with a normal response, in whom HC was discontinued. In these 13 patients, the median peak cortisol level to postoperative CRH stimulation was 480 (340--543) nmol/L, whereas the median peak cortisol level during the second test were 672 (570--890) nmol/L (*P* \< 0.001). The clinical characteristics of these patients are detailed in Table [2](#Tab2){ref-type="table"}. Based on the results of the CRH test 4 patients did not receive HC directly after surgery, or only if necessary. In two of these patients (Table [3](#Tab3){ref-type="table"} patient 2 and 8) the physician defined the HPA axis as normal based on the peak cortisol of the CRH test (540 and 543 nmol/L respectively). No clinical events were reported.Table 2Patients incorrectly diagnosed with adrenal insufficiency based on the CRH test directly after surgeryGenderAge at time of surgery (years)DiagnosisCHR test peak cortisol (nmol/L)HC after surgery (y/n)Follow-up (years)Confirmation testPeak cortisol (nmol/L)Other deficienciesFollow-upClinical event (y/n)1M53NFA410y3 monthsACTH890LH/FSH, GHDNo optimal reaction CRH test, HC discontinued before confirmation test. After 3 years ITT peak cortisol 860 nmol/Ln2M48Acromegaly540n3.8CRH790NoneAfter CRH-test HPA-axis defined as normal, no HCn3M23Acromegaly480n4.9ITT780NoneAfter CRH test another CRH test and 24 h urine still not sufficient.; ITT after 4 years insufficientn4F26Prolactinoma480y8.9ITT750DIHC until next outpatient appointment; 5 years loss to follow-up; recurrence of prolactinoma treatment with Dostinex. Did not use HC. Eight years after surgery two sufficient ACTH tests and 1 year later normal ITTn5M53NFA440y1 monthCRH710GHDHC discontinued after CRH test (9 years after surgery RT)n6F62NFA469y7 monthsITT696GHDAfter 4 months ACTH peak cortisol 580 therefore stop HC. Three months later ITTn7M59NFA457y7 monthsACTH672TSH, LH/FSH, GHDHC discontinued; after 5 months ACTH test insufficient peak cortisol 445 nmol/L. Followed by three more ACTH tests (7--9 months after surgery) all normal cortisol response. ITT 1 year after surgery however nadir 2.3 mmol/L; cortisol peak 574 nmol/L.n8F72Acromegaly543n1.2CRH665NoneHPA-axis defined as normal, no HCn9F56NFA520y3.9ITT657PanhypopitAfter 6 months ACTH test normal; 1 month later ITT peak cortisol 550 nmol; HC lowered to 10 mg/day. 10 months later ITT normal response cortisol; stop HC. Two years later another ITTn10M38Acromegaly340y10.3ITT634NoneReceived HC before surgery, discontinued after surgery followed by CRH test after 3 months; peak cortisol 560 nmol/L. Ten years after surgery ACTH test followed by ITT both normal cortisol responses.n11M42Acromegaly530If neccessary11.6ACTH618NoneBased on CRH only HC if necessary. Shortly after CRH test ACTH test with normal cortisol response; no HC necessary. 11 yrs later another ACTH testn12F42NFA482y1.3CRH606NoneSix months after surgery 1st ACTH test; insufficient cortisol response; followed by four ACTH tests within 6 months. All insufficient cortisol response. Followed by a CRH tests with a sufficient response.n13F39Acromegaly500y4.1ITT570NoneFour months after surgery 2nd CRH test still insufficient cortisol response; continue HC. 1 year later ITT; peak cortisol 520 nmol/L. 3 years later 2nd ITT sufficient stop HCn*M* male, *F* female, *NFA* non functioning adenoma; *n* no, *y* yes, *DI* diabetes insipidus, *ITT* insulin tolerance test, *CRH* corticotropin releasing hormone, *HC* hydrocortisone, *GHD* growth hormone deficiencyTable 3Patients who appeared to be adrenal insufficient based on a second test or basal serum cortisol concentration during follow-upGenderAge at time of surgery (years)DiagnosisCHR test peak cortisol (nmol/L)HC after surgery (y/n)Follow-up (years)Confirmation testPeak cortisol (nmol/L)Other deficienciesFollow-upClinical event (y/n)1M55NFA750n2 monthsITT512PanhypopitBefore surgery panhypopituitarism; ITT after 2 months insufficiëntn2M50NFA690n1.7ITT510PanhypopitNot all results known when patient left hospital. Appeared to be TSH- and GH deficient. Outpatient follow-up 1st ITT sufficient; 2nd ITT insufficientn3M19NFA780n6.5ITT480PanhypopitAfter surgery gonadotrophic deficiency; ITT 2002 sufficient; ITT insufficiënt; corticotrope and GH deficiency; start suppletionn4F50NFA640y1.8ITT410PanhypopitAfter surgery HC; follow-up after 1 year Metyrapone test insufficient; 1 yr later ITT still insufficientn5F53NFA1100y2 monthsMetyrapone test90TSH, GHDBefore surgery TSH deficiency and hypocortisolism; Start HC after surgery; 2 months after surgery ACTH and Metyrapone test both insufficientn6M60NFA600y6 monthsITT200PanhypopitReceived HC before surgery; continued after surgery; follow-up after 6 monthsn7F57NFA670n3.4Metyrapone test190PanhypopitOne year after surgery new CRH test sufficient. Complaints of tiredness. Two years later metyrapone insufficiëntn1598M54NFA670n4.3ACTH 1 ug170PanhypopitAfter surgery gonadotropic and GH deficiency. After 3 years start rGH; 2 years later low cortisol 24 h urine and hypothyroidism. Euthyreotic state ACTH test insufficiënt start HCn9F78NFA620n3 monthsMetyrapone test120NoneCardial problems; follow-up in outpatient clinicn84.910F77NFA610y2 daysMetyrapone test90TSH, DIBased on low basal serum cortisol levels start HC; 2 days after CRH metyrapone test insufficientn79.511F50NFA770n7Metyrapone test90Gonadotrope, GHDSeveral years no complaints no insufficiency; 2002 ITT GHD followed by therapy; 2004 metyrapone insufficientn10712F67NFA600y1.4ITT4PanhypopitDirectly post surgery probably panhypopit because of lesion/rupture pituitary stalk. No basal ACTH production with stimulation after CRH; Start HCn13M38NFA797n3 monthsBasal serum cortisol90PanhypopitBefore surgery panhypopit; CRH test normal. Three months after surgery complaints with low basal serum cortisol. Start HCn14M39NFA660y5 monthsACTH-test300GHD, gonadotrope, DIBefore surgery panhypopituitarism. Probably HC during CRH test after surgeryn*M* male, *F* female, *NFA* non functioning adenoma, *n* no, *y* yes, *DI* diabetes insipidus, *ITT* insulin tolerance test, *CRH* corticotropin releasing hormone, *HC* hydrocortisone, *GHD* growth hormone deficiency

In 20 of these 42 patients with a median CRH stimulated cortisol concentration of 194 (6--510) nmol/L, no additional stimulation test of adrenal function was performed during follow-up. Persistent adrenal insufficiency was considered to be present in these 20 patients because of pre-existent panhypopituitarism before or immediately after surgery (n = 12), pre-existent isolated severe adrenal insufficiency before surgery (n = 4) or very low basal serum cortisol concentrations (mean 10 nmol/L) during follow-up after surgery (n = 4). Accordingly, all these patients received hydrocortisone supplementation directly after the post surgical CRH test until now.

Patients with a normal postoperative cortisol response to CRH (n = 102) {#Sec10}
-----------------------------------------------------------------------

The peak levels of cortisol during the postoperative CRH-test classified 102 of the 144 patients with normal pituitary-adrenal function (peak cortisol \> 550 nmol/L) (Fig. [1](#Fig1){ref-type="fig"}). In 75 of these 102 patients, adrenal function was assessed during follow-up using a second stimulation test in the remaining 27 no stimulation test was used because of basal serum cortisol levels \>550 nmol/L (n = 12), normal urine cortisol levels (n = 3), short follow-up between repeated surgery or additional radiotherapy (n = 2), and follow-up \<1 year (n = 2) or unspecified reasons (n = 7). One patient returned within 3 months after surgery with complaints and basal postabsorptive serum cortisol levels of 90 nmol/L and HC was started without additional stimulation test. The ITT was used in 49 of the 75 patients, the CRH test in 11 patients, the ACTH stimulation test in 11, and the metyrapone test in four patients. A normal response to these tests was found in 62 patients. However, 13 patients had an insufficient adrenal response to these tests. With the inclusion of the patient with very low basal serum cortisol levels (see above), 14 patients were classified as adrenal insufficient (Table [3](#Tab3){ref-type="table"}). Thirteen of these 14 patients had been diagnosed with any other additional pituitary insufficiencies and eight of these patients (57%) had panhypopituitarism. Six patients already received HC directly after surgery. None of these 14 patients experienced any clinical event related to cortisol deficiency.

Prevalence of additional pituitary insufficiency {#Sec11}
------------------------------------------------

A total of 73 patients had additional pituitary insufficiency. The prevalence of additional pituitary insufficiency was significantly higher in patients diagnosed with an insufficient CRH stimulation test after surgery compared to patients with a normal test result (any hypopituitarism *P* \< 0.001; GHD *P* \< 0.001; TSH deficiency *P* \< 0.001; LH/FSH deficiency *P* = 0.001).

Discussion {#Sec12}
==========

This study evaluated the postoperative response of cortisol to CRH stimulation in a large cohort of patients after TS for pituitary adenomas compared with the adrenal function assessed during postoperative follow-up. The second adrenal function test documented a normal cortisol response in 31% of the patients with a decreased cortisol response to CRH stimulation directly after surgery. Conversely, the second adrenal stimulation test documented an insufficient cortisol response in 14% of the patients with a normal cortisol response to direct postoperative CRH stimulation. Therefore, the postoperative CRH test does not reliably predict adrenal function after TS for pituitary adenomas in all patients. Nonetheless, our substitution strategy of hydrocortisone guided by the postoperative cortisol responses to CRH did not result in any case of adrenal crises in our patients.

Although CRH stimulation has been incorporated in the diagnostic procedures of ACTH dependent Cushing's syndrome \[[@CR21]--[@CR23]\], reports on the use of CRH stimulation to assess cortisol dependency after transsphenoidal surgery for other pituitary adenomas are scarce. We found three publications that assessed pituitary function using CRH, but these were not specifically in patients after transsphenoidal surgery \[[@CR8], [@CR9]\]. Dullaart et al. \[[@CR9]\] and Schmidt et al. \[[@CR8]\] compared the CRH test with basal serum cortisol levels and found no higher diagnostic applicability of the CRH test to basal morning cortisol levels. In contrast, Maghnie et al. concluded that the CRH test provided better results than the short Synacthen test (SST) and low-dose short Synacthen test (LDSST), and that CRH may be useful in patients who have a contraindication for ITT \[[@CR7]\].

In the current study, the postoperative CRH stimulation test classified 42 of the 144 patients with hypocortisolism. However, 13 of these patients had sufficient adrenal function during follow-up. There are several explanations for these discrepant results. They may be related to differences in cut-off values of the different tests. Regularly accepted cut-off values (500--550 nmol/L) have been defined for the ITT, which still remains the gold standard test for the assessment of the HPA-axis. For the CRH test, some authors have proposed different cut-off values for peak cortisol responses. For example, Schmidt et al. \[[@CR8]\] reported an optimal peak cortisol cut off of \<377 nmol/L, yielding a 96% specificity, but poor sensitivity of 76% for the diagnosis of adrenal insufficiency. A sensitivity of 100% was reached using a peak cortisol levels of 514 nmol/L (with a specificity of 32%), and 100% specificity with peak cortisol levels of 349 nmol/L (sensitivity 66%). Dullaart et al. found that a peak cortisol value of 420 nmol/L reflected 100% specificity, but 100% sensitivity for the CRH test was only reached using a peak cortisol of 615 nmol/L. Because in our center the CRH test is used as a screening test for hypocortisolism after TS to identify those patients that require hydrocortisone supplementation, we applied a generally accepted stringent criterion of 550 nmol/L. The data indicate that this choice for a higher sensitivity of the CRH test is at the expense of a lower specificity. In other words, using this strategy a higher proportion of patients will be incorrectly diagnosed with adrenal insufficiency. Based on the available literature the use of a cut-off levels of peak cortisol of 514 nmol/L would have resulted in 4/13 patients which would not have been diagnosed with adrenal insufficiency, but with the criteria suggested by Dullaart et al. even more patients would have had discrepant results \[[@CR8], [@CR9]\].

Recovery of preoperative adrenal insufficiency following TS has been described previously \[[@CR24], [@CR25]\]. In a recent study that compared the ITT response at 3 and 12 months after TS, recovery of adrenal function was demonstrated within the first year \[[@CR26]\]. In agreement, we found a normal function of the HPA-axis in eight patients within the first year after surgery who were initially diagnosed as being adrenal insufficient, indicating the necessity of an extensive follow-up in patients after surgery within one year.

In the current study, the postoperative CRH test classified 102 of the 144 patients as having a normal functioning of the HPA-axis based on the post-operative CRH test. Fourteen percent of these patients later proved to have hypocortisolism by a second test. These discrepant test results can be potentially life-threatening because these patients are at risk for adrenal crises. It is possible that additional pituitary insufficiencies affected pituitary-adrenal function. Growth hormone and thyroid hormone deficiency can influence these test results. Growth hormone replacement therapy in patients with growth hormone deficiency may also play an important role because of the influence of GH on the cortisol metabolism. Growth hormone stimulates 11-β hydroxysteroid dehydrogenase (11βHSD-1), leading to increased cortisol-cortisone interconversion \[[@CR27]\]. The use of GH replacement therapy in GH-deficient patients may therefore unmask cortisol deficiency \[[@CR28], [@CR29]\]. This may also be the case in some of our patients, because their adrenal insufficiency became clear after start of rhGH therapy. Despite all the confounding factors none of our patients had a clinical event.

In conclusion, the CRH-test can be safely used to guide hydrocortisone substitution after TS. Nonetheless, the cortisol response to this test cannot reliably predict adrenal function in all patients during longer follow-up after TS. We therefore recommend to perform a second test of pituitary adrenal function during longer follow-up, e.g. 3--6 months after surgery (see Fig. [2](#Fig2){ref-type="fig"}). This approach is not required in patients with an impaired postoperative cortisol response to CRH, who have multiple pituitary insufficiencies.Fig. 2Proposed algorithm for the postoperative follow-up of adrenal function in non ACTH dependent pituitary disease (*HC* hydrocortisone)
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